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Human myelogenous leukaemia K562 cells were induced to undergo megakaryocytic differentiation by treatment with phorbol ester
12-O-tetradecanoylphorbol-13-acetate (TPA) (20nM, 24–72h). The steady-state level of nucleophosmin/B23 mRNA decreased
during the TPA-induced differentiation. There was also decrease in the level of cellular nucleophosmin/B23 protein and appearance
of its degraded product (25kDa) during the TPA-induced differentiation. Furthermore, K562/B23 (wild type), K562/D1 (D280–294)
and K562/D2 (D263–294) cells were less, while K562/D3 (D244–294) cells were more responsive to TPA-induced differentiation as
compared to K562/vector or parental K562 cells. Activation of the ERK/MAPK was observed in parental K562 cells upon TPA
treatment (5nM, 5–30min). As compared to K562/vector cells, less activation of ERK/MAPK was observed in K562/D2 cells, while
ERK/MAPK was highly activated in K562/D3 cells upon TPA treatment. Our results indicate that nucleophosmin/B23 plays an
important role in TPA-induced differentiation of K562 cells and the amino acids 244–294 at C-terminal of nucleophosmin/B23 could
be an important site for regulation of cellular response to differentiation.
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A coordination and balance between cell proliferation, differentia-
tion and apoptosis is crucial for normal development and tissue-
size homeostasis in the adult (Li and Yuan, 1999). Dysregulation of
this tightly controlled mechanism of cell differentiation and
apoptosis may result in cancer. Mutated cell survival and
inappropriate proliferation, disrupting this balance, would be
expected to contribute to oncogenesis (Wyllie, 1997). Tumour
cells often acquire damage to genes that directly regulate cell
growth to result in uncontrolled cell proliferation. The identifica-
tion of genes and their products that are involved in response to
growth stimuli is essential for understanding of the normal cell
growth and its regulation (Wolff, 1997).
Between cancer and normal cells, one important difference is the
hyperactivity and the pleomorphism of the nucleoli in cancer cells
(Busch et al, 1963; Busch, 1990). The nucleolus includes many
proteins such as enzymes for RNA synthesis (RNA polymerase I)
and processing (exonuclease and endonuclease), the proteins of
preribosomes and nonribosomal proteins (Prestayko et al, 1974).
Recent reports have shown that nonribosomal proteins of the
nucleolus participate in regulating nucleolar activity that is
associated with cell growth (Valdez et al, 1994). Of the proteins
found in elevated amounts in nucleoli of cancer cells, a
nonribosomal protein nucleophosmin/B23 is present in one of
the largest amounts on two-dimensional gel electrophoresis
(Prestayko et al, 1974; Orrick et al 1973). Nucleophosmin/B23,
being more abundant in tumour cells than in normal resting cells,
has a potential role in increased nucleolar activity that is necessary
for cell proliferation (Feuerstein et al, 1988; Chan et al, 1989); a
role as a cytoplasmic/nuclear shuttle protein (Borer et al, 1989);
relieves transcription repression by YY1 (Inouye and Seto, 1994);
binds nuclear and nucleolar localisation signals on the HIV Type 1
Rev protein (Fankhauser et al, 1991) and the human T-cell
leukaemia virus-1-Rex protein (Adachi et al, 1993); binds cell
cycle-regulated nucleolar protein p120 (Valdez et al, 1994); inhibits
DNA-binding and transcriptional activity of interferon regulatory
factor-1 (IRF-1), which is a tumour suppressor (Tanaka et al, 1994;
Kondo et al, 1997). Nucleophosmin/B23 overexpression at the
RNA and protein levels may contribute to the onset of cancer
(Feuerstein et al, 1988; Chan et al, 1989; Kondo et al, 1997).
Blockage of nucleophomin/B23 expression with its antisense
oligonucleotides has shown that nucleophosmin/B23 is crucial
for making cancer cells resistant to induction of differentiation and
apoptosis (Hsu and Yung, 1998; Liu and Yung, 1998; You et al,
1999). It thus appears that an excess of nucleophosmin/B23 is an
important cause of cancer and not just a consequence.
The K562 cell line was originally established from the pleural
effusion of a patient with chronic myelogenous leukemia (CML) in
the blastic phase (Tabilio et al, 1983). The K562 cell line can be
induced to differentiate towards megakaryocytic differentiation by
the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and
resulted in loss of proliferative capacity (Alitalo, 1990). 12-O-
tetradecanoylphorbol-13-acetate likely activates pathways of signal
transduction regulating cell proliferation and differentiation. K562
cell line becomes an important tool for the study of early events Received 21 January 2003; revised 7 May 2003; accepted 8 May 2003
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sinvolved in megakaryocytic differentiation. The aim of our present
study was to investigate the role of nucleophosmin/B23 in
megakaryocytic differentiation. Attempt was made to elucidate
the effect of C-terminal deletion of nucleophosmin/B23 on TPA-
induced differentiation of K562 cells. Our results demonstrate that
nucleophosmin/B23 plays a role in the control of cellular response
to TPA-induced megakaryocytic differentiation of K562 cells.
MATERIALS AND METHODS
Drugs and antibodies
12-O-tetradecanoylphorbol-13-acetate was purchased from Sigma
Chemical Co. (St Louis, MO, USA). Monoclonal anti-phospho-ERK
and anti-ERK antibodies (Abs) were from Santa Cruz (Santa Cruz,
CA, USA). Monoclonal anti-CD41a-FITC and anti-CD42b-FITC
Abs were purchased from BD Pharmingen (San Diego, CA, USA).
Antiactin, anti-FLAG and fluorescein-conjugated goat anti-mouse
IgG Abs were from Sigma. Monoclonal Ab to nucleophosmin/B23
was kindly provided by Dr PK Chan, Department of Pharmacol-
ogy, Baylor College of Medicine, Houston, TX, USA.
Cell culture
K562 leukaemia cells were grown in RPMI-1640 medium (Life
Technologies, Rockville, MD, USA) supplemented with 10% heat-
inactivated foetal bovine serum (Hyclone, UT, USA), 2mM
glutamine, 50Uml
 1 penicillin and 50mgml
 1 streptomycin in a
5% humidified incubator at 371C. K562 cells were treated with TPA
(80nM). Every 24h for 4 days, cultures were harvested and
monitored for cell number by counting cell suspensions with
haemocytometer. Cell viability was assessed by exclusion of 0.2%
trypan blue.
Assays of cellular differentiation
TPA-induced megakaryocytic differentiation of K562 cells was
assayed by measuring the expressions of differentiation-specific
membrane antigens (CD41a and CD42b). Cells were washed and
suspended in ice-cold PBS containing 10% foetal calf serum. Anti-
CD41a-FITC or anti-CD42b-FITC Ab was added for 30min at 41C
and the cells were then washed twice with 2ml of PBS containing
10% foetal calf serum. The percentages of CD41a- or CD42b-
positive cells and fluorescence intensities were evaluated by
FACScan. The threshold value discriminating positive from
negative cells was set as the fluorescence level below which 95%
of control (TPA untreated) cells occurred.
Immunoblot analysis
Cells were harvested, washed twice in ice-cold PBS and lysed in
RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1%
SDS, 20mM Na2HPO4, 100mM NaCl, 20mM NaF, 0.2mM PMSF,
1m M DTT, 30mgml
 1 DNase and 30mgml
 1 RNase). The lysates
were boiled in SDS sample buffer (62.5mM Tris, pH 6.8, 5% b-
mercaptoethanol, 10% glycerol, 2% SDS, 0.001% bromophenol
blue) and the cell extract was fractionated by 10% SDS–
polyacrylamide gel electrophoresis (SDS–PAGE). The separated
proteins in SDS–PAGE were electrotransferred to Hybond-PVDF
membrane (Amersham Pharmacia). The PVDF membrane was
then soaked in a blocking solution (5% nonfat milk in TBST buffer
(20mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.1% Tween 20)) for 1h at
room temperature. The soaked PVDF membrane was then
incubated with primary antibody overnight at 4
oC, washed with
TBST buffer three times for 15min each and incubated at room
temperature for 1h in horseradish peroxidase-conjugated goat
anti-mouse IgG Ab (Promega, Madison, WI, USA). The membrane
was washed with TBST buffer three times for 15min each.
Immunoreactivity was determined using the chromogenic devel-
opment or the enhanced chemiluminescence reaction (ECL,
Amersham).
RNA analysis
Total RNA was prepared from K562 cells by ULTRASPEC
TM RNA
Isolation System (Biotecx, Houston, TX, USA). For Northern blot
analysis, aliquots of 5mg of RNA were separated by 1.2%
formaldehyde agarose gel electrophoresis, transferred to nylon
membranes (Amersham) by downward alkaline capillary method
and fixed to the membrane by drying at 801C for 30min. The
nucleophosmin/B23 cDNA labelled with [a-
32P]dCTP using a
random primed kit (Promega, Madison, WI, USA) was employed
as a probe for detection of homologous mRNA. Prehybridisation
was carried out overnight at 421C in a solution containing 50%
formamide, Denhardt’s solution, 5  SSC (1  SSC¼0.15 M NaCl,
0.015 M sodium citrate), 0.1% SDS, and 250mgml
 1 denatured
salmon sperm DNA. Radiolabelled probe at a specific activity of
1–2  10
8c.p.m.ml
 1 was hybridised with total RNA in the same
solution for 24h at 421C. Washing of the membranes for the
probes was twice in 2  SSC and 0.5% SDS at 421C for 10min, and
once in 0.1  SSC and 0.5% SDS at room temperature for 30min.
The radioactive nucleophosmin/B23 homologous mRNA was
determined by autoradiography with phosphoimager or with
intensifying screen at  701C.
Plasmid
Full-length nucleophosmin/B23 cDNA in plasmid PET-T7 (which
was generously given by Dr Pui Kwong Chan, Department of
Pharmacology, Baylor College of Medicine, Houston, TX, USA)
was amplified by PCR using 50-GCG TGC CGC CAC CCG ATG
GAA GAT TCG ATG G-30 and 50- GTT TAA ACT ATT TTC TTA
AAG AGA CTT-30 as primers. Amplified PCR products were then
separated and isolated from 1% agarose gel. The 0.9 kilobase
nucleophosmin/B23 cDNA was then subcloned into the cloning
site of the vector pCRt3 supplied in the Eukaryotic TA cloning kit
(Invitrogene, Carlsbad, CA, USA). The orientation of the cDNA in
pCRt3 was determined by nucleotide sequencing using the
Sequence kit (Amersham Pharmacia Biotech, Buckinghamshire,
England, UK). The plasmid clones containing the nucleophosmin/
B23 cDNA in the sense orientation in respect to the cytomegalo-
virus (CMV) immediate-early promoter of pCRt3 was referred as
pCR3-B23.
For full-length nucleophosmin/B23 cDNA clones (T7), the N-
terminal primer was 50- ACC ATG GAC TAC AAA GAC GAT GAC
GAC AAG CTT ATG GAA GAT TCG ATG GAC-30. This primer
encoded an AUG translation initiation codon followed by the
codons for the eight amino acids in the FLAG epitope (Asp-Tyr-
Lys-Asp-Asp-Asp-Asp-Lys) and six amino acids from nucleophos-
min/B23. The C-terminal primer that contained the BamHI site
was 50-CGC CGC GGA TCC TTA AAG AGA CTT CCT CCA CT-30.
For carboxyl-terminal deletion mutants, the N-terminal primer
was the same as T7 clone as described above. C-terminal primers
were up to deletion sites and stop codon (TAA) was added in the
terminus. The C-terminal primers for deletion mutants were: D1,
50-GCG CCT AGG TTA AGT CAT CCG GAA GC-30 (D280–294);
D2, 50-GCG CCT AGG TTA GGG AAG AGA ACC ACC-30 (D263–
294); D3, 50-GCG CCT AGG TTA AGA ACT AGG TCC-30 (D244–
294). Plasmid pET-T7 nucleophosmin/B23 cDNA was used as a
template. After PCR amplification, the FLAG tag and the coding
region of nucleophosmin/B23 should be in frame. The PCR
products were cloned into pCR3.1 vector supplied in Eukaryotic
TA cloning kit (Invitrogene, Carlsbad, CA, USA). The orientation
of each construct was analysed by restriction mapping and full-
length nucleotide sequencing using the Sequence kit (Amersham
Pharmacia Biotech). The plasmid clones containing the full-length
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CMV immediate-early promoter.
Establishment of stable clones
The transfection was performed using Lipofectaminet Reagent
(Life Technologies) method. K562 cells were seeded at a density of
5 10
5 per well in 1.0ml serum-free medium. A measure of 2.5mg
of pCR3.1-FLAG-B23, pCR3.1-FLAG-D1, pCR3.1-FLAG-D2,
pCR3.1-FLAG-D3 plasmid constructs or pCR3 vector alone and
12.5mg of lipofectamine reagents in serum-free medium were
mixed gently. The mixture was incubated for 30min at room
temperature, added to K562 cells and was incubated overnight at
371C in the CO2 incubator. The culture was further incubated in
fresh RPMI-1640 medium for 48h. The transfected cells were then
distributed in 24-well plates at 500 cells per well, and 800mgml
 1
G418 was added for selection of stably transfected clones. After
selection with G418 for 3–5 weeks, individual clones were
expanded to mass cultures and subsequently assayed for
nucleophosmin/B23 or its deletion mutant expression. The
transfectants were maintained in culture medium supplemented
with 200mgml
 1 of G418. Clones overexpressing nucleophosmin/
B23 or its deletion mutants were screened by Western blot using
monoclonal anti-FLAG Ab.
RESULTS
Decrease of nucleophosmin/B23 mRNA during
TPA-induced differentiation of K562 cells
To investigate whether nucleophosmin/B23 was involved in
megakaryocytic differentiation, we first examined nucleophos-
min/B23 mRNA expression during TPA-induced differentiation of
human myelogenous leukaemia K562 cells. K562 cells can be
induced to differentiate towards megakaryocytic lineage, char-
acterised by changes in cell morphology, cell growth arrest and
acquisition of megakaryocytic surface markers (Braverman et al,
1986; Alitalo, 1990). Culturing the cells for 24–72h with 20nM TPA
caused growth inhibition (Figure 1A) and a marked increase in
differentiation surface marker, CD41a or CD42b (Figure 1B, C).
The viability of the cells was over 90% as measured by trypan blue
method over 72h of 20nM TPA treatment (data not shown). A
single mRNA band hybridizing with nucleophosmin/B23 cDNA
probe was observed in Northern blot of rapidly proliferating
leukaemic K562 cells (Figure 2). After 72h of 20nM TPA treatment,
nucleophosmin/B23 mRNA expression decreased to less than 20%.
In parallel, c-myc mRNA expression was also decreased during
TPA-induced differentiation (Figure 2).
Decrease of nucleophosmin/B23 protein level during TPA-
induced differentiation of K562 cells
Total cellular protein samples (containing equal amounts of
protein) from control untreated K562 cells and the K562 cells
treated with 20 or 40nM TPA for various times (1–3 days; 3–48h)
were separated by 10% SDS–PAGE and subsequently analysed by
Western blot immunoassay. The lower and upper panels of Figure
3A or B showed the Coomassie blue-stained SDS–PAGE and
chromogenic diagrams of Western blot analysis, respectively. After
1–3 days of TPA (20–40nM) treatment, the Western blot showed
that the cellular protein level of nucleophosmin/B23 decreased and
a new band at 25kDa appeared (Figure 3A). The appearance of
25kDa band was detected after 18h of 20nM TPA treatment
(Figure 3B). Caspase-3 inhibitor (25mM; Ac-DEVD-CHO) blocked
the decrease of nucleophosmin/B23 and the appearance of the new
band at 25kDa that could possibly be the degraded form of
nucleophosmin/B23 (data not shown).
Establishment of nucleophosmin/B23 wild-type and
deletion mutants overexpressed stable clones
Attempt was made to investigate which domain of nucleophosmin/
B23 was involved in TPA-induced differentiation of K562 cells.
K562 cells were transfected with nucleophosmin/B23 wild-type or
deletion constructs fused each at its amino terminus to the FLAG
epitope, encoding eight amino acids (Asp-Tyr-Lys-Asp-Asp-Asp-
Asp-Lys) (Figure 4A). After G418 selection, stable clones of K562
cells overexpressing nucleophosmin/B23 wild-type and various
deletion constructs, namely K562/B23 (wild type), K562/D1
(D280–294), K562/D2 (D263–294) and K562/D3 (D244–294),
were established. We obtained two clones each from various
stable clones of nucleophosmin/B23 wild-type or deletion mutants.
Western blot analysis with anti-FLAG antibody showed that
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Figure 1 Effect of TPA on cell growth and differentiation of K562 cells.
(A) The growth curve after 20nM TPA treatment for various times (24–
72h). Cultures were harvested and cell numbers were counted with a
haemocytometer. Points, means of triplicate7SD. Viability of the cells was
490% under these TPA treatments. (B,C) K562 cells were treated with
20nM TPA for 72h and the differentiation was assayed by measuring the
expressions of differentiation markers. Expressions of the CD41a or
CD42b were evaluated by flow cytometry using specific anti-CD41a or
anti-CD42b FITC-conjugated monoclonal antibody.
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snucleophosmin/B23 wild-type and deletion proteins were over-
expressed in those stable clones (Figure 4B) and were distinguish-
able from cellular endogenous nucleophosmin/B23. The apparent
mobility of the proteins corresponded well with the predicted
molecular weight of each deletion mutant. The predicted sizes were
as followed: FLAG-nucleophosmin/B23, 39kDa; FLAG-D1, 36kDa;
FLAG-D2, 35kDa; FLAG-D3, 33kDa. K562/B23, K562/D1, K562/D2
and K562/D3 cells grew similarly and showed no morphological
changes as compared with the control vector-transfected K562 cells
(K562/vector) or the parental cells (K562 cells) (data not shown).
Assessment of cellular response of nucleophosmin/B23
wild-type and deletion mutant overexpressed cells to
TPA-induced differentiation
Flow cytometric analysis of surface markers showed that expres-
sion of CD41a or CD42b was lower in K562/B23 (wild type), K562/
D1 (D280–294) or K562/D2 (D263–294) cells as compared to
control vector-transfected cells (K562/vector) or the parental cells
(K562 cells) treated with 20nM TPA for 72h (Figure 5). In contrast,
expression of CD42b was higher in K562/D3 (D244–294) cells as
compared to K562/vector or parental K562 cells treated with 20nM
TPA for 72h (Figure 5). Our results showed that K562/B23 (wild
type), K562/D1 (D280–294) and K562/D2 (D263–294) cells were
less, while K562/D3 (D244 – 294) cells were more responsive to
TPA-induced differentiation as compared to K562/vector or
parental K562 cells. These results indicated that amino acids
244–294 of the nucleophosmin/B23 protein could be an important
site for regulation of cellular response to differentiation. It is
possible that deletion of C-terminal (amino acids 244–262) of
nucleophosmin/B23 leads to the loss of its binding ability with
some regulatory factor(s). The factor(s) being free from complex-
ing with nucleophosmin/B23 is then functional for induction of
differentiation.
Activation of ERK upon TPA treatment
Previous studies have shown that ERK/MAPK is activated during
megakaryocytic differentiation of K562 cells (Racke et al, 1997;
Whalen et al, 1997). To elucidate whether nucleophosmin/B23 was
involved with ERK/MAPK in TPA-induced differentiation, we
examined the effect of TPA on ERK activation in nucleophosmin/
B23 deletion mutant overexpressed K562/D2 (less responsive to
TPA) and K562/D3 (more responsive to TPA) cells as compared to
K562/vector cells (Figure 6). Activation of the ERK/MAPK was
observed in parental K562 cells upon TPA treatment (5nM,5 –
30min) (Figure 6A). As compared to K562/vector cells, less
activation of ERK/MAPK was observed in K562/D2 cells, while
ERK/MAPK was highly activated in K562/D3 cells upon TPA
treatment (5nM, 10min) (Figure 6B).
DISCUSSION
This study investigated the possibility that nucleophosmin/B23
played an important role in cellular susceptibility to TPA-induced
megakaryocytic differentiation of K562 cells. We demonstrate that
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Figure 2 Decrease of nucleophosmin/B23 mRNA during TPA-induced
differentiation of K562 cells. K562 cells were treated with 20nM TPA for
72h. Cells were then harvested and the total RNA was prepared.
Northern blot analysis was performed with 5mg of RNA for each sample.
The
32P-labelled nucleophosmin/B23 (B23) cDNA and c-myc probes were
employed for detection of homologous mRNA. The same filter was
hybridised with
32P-labelled 18S cDNA probe that was used as a control
for the amount of RNA loaded.
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Figure 3 Decrease of nucleophosmin/B23 protein level during TPA-
induced differentiation of K562 cells. (A) K562 cells were treated with 20
or 40nM TPA for various times (1–3 days) or (B) treated with 20nM TPA
for various times (3–48h). Cells were harvested and 10mg of total cellular
proteins was separated by 10% SDS–PAGE stained with Coomassie blue
(lower panels) or blotted onto PVDF membrane (upper panels).
Nucleophosmin/B23 (B23) protein was detected by Immunoblot using
anti-nucleophosmin/B23 monoclonal Ab and the chromogenic develop-
ment.
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snucleophosmin/B23 mRNA and protein are decreased after TPA
treatment in parental K562 cells. Stable clones of K562 cells
overexpressing nucleophosmin/B23 wild-type and various deletion
constructs, namely K562/B23 (wild type), K562/D1 (D280–294),
K562/D2 (D263–294) and K562/D3 (D244–294) have been
established to investigate which domain of nucleophosmin/B23 is
involved in TPA-induced differentiation of K562 cells. Our results
have shown that K562/B23 (wild type), K562/D1 (D280–294) and
K562/D2 (D263–294) cells are less, while K562/D3 (D244–294)
cells are more responsive to TPA-induced differentiation as
compared to K562/vector or parental K562 cells. These results
indicate that amino acids 244–294 of the nucleophosmin/B23
protein may be an important site for regulation of cellular
response to TPA-induced differentiation of K562 cells. C-terminal
end has been shown to be important site of nucleophosmin/B23.
DNA polymerasea binding site is at the C-terminal. A total of 12
amino acids at the C-terminal end of B23.1, which are absent in
B23.2, is essential for full stimulation of the DNA polymerase a
(Umekawa et al, 2001). Deletion of C-terminal (amino acids 244–
262) of nucleophosmin/B23 may lead to the loss of its binding
ability with important growth regulatory factor(s). Stimulation of
growth activity was inhibited or factor(s) being free from
complexing with nucleophosmin/B23 is then functional for
induction of differentiation.
In RA-induced differentiation of HL-60 cells, the involvement of
nucleophosmin/B23 in oncogenic activity is that nucleophosmin/
B23 may bind and inactivate the tumour suppressor in cancer cells
(Hsu and Yung, 2000). IRF-1 acts as a transcriptional activator in
the interferon system and as a tumour suppressor (Harada et al,
1989,1993). Nucleophosmin/B23 could bind to IRF-1, interfere
with IRF-1 binding to IRF-1 response elements, inhibit the IRF-1
transcriptional activity and manifest oncogenic potential (Kondo
et al, 1997; Hsu and Yung, 2000). Interaction of nucleophosmin/
B23 with some factor(s), such as tumour suppressor, may be an
important mechanism in the control of cellular response to
induction of cellular differentiation and apoptosis. The availability
of the binding site of nucleophosmin/B23 to interact with tumour
suppressor is the basis for the cells being abnormal and resistant to
induction of differentiation and apoptosis. In the present study,
little induction of IRF-1 protein was observed in TPA-induced
differentiation of K562 cells. All GST-nucleophosmin/B23 and the
deletion mutants (D1-D3) could bind the in vitro translated
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Figure 4 Schematic representation of nucleophosmin/B23 wild-type and
deletion mutants. (A) The human nucleophosmin/B23 cDNA or its
deletion mutants were cloned into the expression vectors pCR3.1 in frame
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Figure 5 Assessment of cellular response of nucleophosmin/B23 wild-
type and deletion mutant overexpressed cells to TPA-induced differentia-
tion. The parental K562 cells, the control vector-transfected K562 cells
(K562/vector) and the stable clones (two for each) of nucleophosmin/B23
wild-type (K562/B23) or deletion mutants (K562/D1, K562/D2 or K562/
D3) were treated with 20nM TPA for 72h. After the cells were harvested,
expressions of CD41a (A) or CD42b (B) were evaluated by flow
cytometry using specific anti-CD41a or anti-CD42b FITC-conjugated
monoclonal antibody. Bars, means of triplicate7SD. *Po0.05, as
compared with K562/vector cells under same TPA treatment.
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sIRF-1 (our unpublished data). Nucleophosmin/B23 may act
through other factors rather than IRF-1 in the control of TPA-
induced differentiation in K562 cells.
Decrease of nucleophosmin/B23 has been observed in cells
during induction of cellular differentiation and apoptosis (Hsu and
Yung, 1998; Liu and Yung 1998). More drastic decrease of
nucleophosmin/B23 is detected in NIH-3T3 than in ras-trans-
formed cells during the apoptosis induced by serum deprivation
(Chou and Yung, 2001). Nucleophosmin/B23 in serum-deprived
NIH-3T3 cells is found to be highly unstable, with a half-life of less
than 4h. Cell-permeable caspase-3 inhibitor (10–25mM) blocks the
decrease of nucleophosmin/B23 induced by serum deprivation in
NIH-3T3 cells (Chou and Yung, 2001). These studies indicate that
increased stability of nucleophosmin/B23 is involved in antiapop-
tosis. While no evidence of cleavage of nucleophosmin/B23 under
apoptotic or necrotic conditions was found in HL-60 cells before
(Bortul et al, 2001), the appearance of its degraded forms has now
been detected in serum-deprived NIH-3T3 (Chou and Yung, 2001)
and TPA-treated K562 cells (the present study). Signalling pathway
and cell specificity involved with the cleavage of nucleophosmin/
B23 in the induction of apoptosis and differentiation need further
investigation.
Mitogen-activated protein kinase (MAPK) modules are involved
in the signal transduction of a wide variety of signals in the
eukaryotic organisms. The ERK/MAPK cascade plays a pivotal role
in several cellular functions. The ERK/MAPK is activated by dual
phosphorylation on a threonine and a tyrosine residue, achieved
by the dual-specificity kinase MAP kinase kinase (MEK) (Waskie-
wicz and Cooper, 1995). In our present study, activation of the
ERK/MAPK is observed in parental K562 cells upon TPA
treatment. As compared to K562/vector cells, less activation of
ERK/MAPK is observed in K562/D2 cells, while ERK/MAPK is
highly activated in K562/D3 cells upon TPA treatment. Our results
indicate that nucleophosmin/B23 plays a role in cellular response
to ERK/MAPK-activated megakaryocytic differentiation of K562
cells.
Nucleolus participates in many other aspects of gene expression
as well (Pederson, 1998). Biosyntheses of signal recognition
particle RNA and telomerase RNA involve a nucleolar stage
(Pederson, 1998) and nucleolus is a site critical to cellular aging
(Johnson et al, 1998). Nucleolar protein nucleophosmin/B23 is
importantly associated with cancer (You et al, 1999) and is
implicated to have a functional role in the apoptotic cascade
(Patterson et al., 1995) and growth control (Hsu and Yung, 1998;
Liu and Yung, 1998). The potentiation ability of nucleophosmin/
B23 antisense in induced cellular differentiation, apoptosis and
inhibition of telomerase activity is particularly interesting and may
lead to the use of antisense construct in cancer treatment. Taken
together, the present study represents one of the few demonstra-
tions of the involvement of a nuclear protein in the control of cell
death/cell differentiation. The detailed mechanism or transduction
cascade involved in nucleophosmin/B23-mediated resistance to
induction of differentiation and apoptosis is under current
investigation.
In conclusion, our results provide evidence that nucleophosmin/
B23 plays an important role in TPA-induced megakaryocytic
differentiation of K562 cells.
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